104,731 Maravai LifeSciences Holdings, Inc. $MRVI Shares Sold by Royce & Associates LP

Royce & Associates LP trimmed its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) by 5.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,703,717 shares of the company’s stock after selling 104,731 shares during the period. Royce & Associates LP owned 0.66% of Maravai LifeSciences worth $13,050,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in shares of Maravai LifeSciences by 0.9% in the first quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock worth $12,069,000 after purchasing an additional 39,600 shares during the period. Dimensional Fund Advisors LP boosted its stake in Maravai LifeSciences by 64.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock valued at $4,015,000 after buying an additional 558,050 shares during the period. Bank of New York Mellon Corp bought a new stake in Maravai LifeSciences during the second quarter valued at $2,230,000. Russell Investments Group Ltd. grew its position in Maravai LifeSciences by 4.9% during the third quarter. Russell Investments Group Ltd. now owns 166,243 shares of the company’s stock worth $1,273,000 after buying an additional 7,699 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Maravai LifeSciences during the second quarter worth about $1,038,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Performance

NASDAQ MRVI opened at $7.40 on Tuesday. Maravai LifeSciences Holdings, Inc. has a 52-week low of $2.80 and a 52-week high of $9.42. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 4.66. The company has a market capitalization of $1.92 billion, a P/E ratio of -17.21 and a beta of 0.61. The company has a fifty day moving average of $7.40 and a 200-day moving average of $5.44.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.03. The company had revenue of $45.85 million during the quarter, compared to analyst estimates of $43.56 million. Maravai LifeSciences had a negative net margin of 30.83% and a negative return on equity of 12.44%. As a group, equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. TD Cowen began coverage on Maravai LifeSciences in a research note on Monday, October 5th. They issued a “buy” rating and a $9.00 target price on the stock. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. UBS Group lifted their price target on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, KeyCorp upgraded shares of Maravai LifeSciences from a “sector weight” rating to an “overweight” rating and set a $11.00 price objective on the stock in a research report on Thursday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.10.

Read Our Latest Stock Analysis on MRVI

Maravai LifeSciences Company Profile

(Free Report)

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.

Featured Articles

Institutional Ownership by Quarter for Maravai LifeSciences (NASDAQ:MRVI)

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.